Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDE849 in DLL3-Expressing Tumors Including SCLC
NCT07174583Phase 2Recruiting
- Sponsor
- IDEAYA Biosciences
- Start
- Oct 2025
- Primary completion
- Jul 2029
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-4849 in small cell lung cancer (SCLC), neuroendocrine carcinoma (NEC), solid tumor, sponsored by IDEAYA Biosciences. Started Oct 2025; status: recruiting.
02
Drugs
SHR-4849
03
Conditions
small cell lung cancer (SCLC)neuroendocrine carcinoma (NEC)solid tumor
Beyond the preview
Go deeper on NCT07174583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174583.